021-51111890
购物车（）
sales@molnova.cn
ADAMTS-5 Inhibitor
CAS No. 929634-33-3
ADAMTS-5 Inhibitor ( —— )
产品货号. M26598 CAS No. 929634-33-3
ADAMTS-5 Inhibitor is a potent ADAMTS-5 (aggrecanase-2) inhibitor, with an IC50 of 1.1 μM. ADAMTS-5 Inhibitor shows >40-fold functional selectivity over ADAMTS-4 (aggrecanase-1).
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥1199 | 有现货 |
|
| 10MG | ￥1758 | 有现货 |
|
| 25MG | ￥2908 | 有现货 |
|
| 50MG | ￥4317 | 有现货 |
|
| 100MG | ￥6229 | 有现货 |
|
| 500MG | ￥12798 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称ADAMTS-5 Inhibitor
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述ADAMTS-5 Inhibitor is a potent ADAMTS-5 (aggrecanase-2) inhibitor, with an IC50 of 1.1 μM. ADAMTS-5 Inhibitor shows >40-fold functional selectivity over ADAMTS-4 (aggrecanase-1).
-
产品描述ADAMTS-5 Inhibitor is a potent ADAMTS-5 (aggrecanase-2) inhibitor, with an IC50 of 1.1 μM. ADAMTS-5 Inhibitor shows >40-fold functional selectivity over ADAMTS-4 (aggrecanase-1).
-
同义词——
-
通路Others
-
靶点Other Targets
-
受体5-HT2A; D1 receptor; D5 receptor
-
研究领域——
-
适应症——
化学信息
-
CAS Number929634-33-3
-
分子量449.9
-
分子式C16H11ClF3N3OS3
-
纯度>98% (HPLC)
-
溶解度——
-
SMILESCn1nc(c(\C=C2/SC(=S)NC2=O)c1SCc1ccc(Cl)cc1)C(F)(F)F
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.1. Rostom SA. Novel fused pyrrole heterocyclic ring systems as structure analogs of LE 300: Synthesis and pharmacological evaluation as serotonin 5-HT(2A), dopamine and histamine H(1) receptor ligands. Arch Pharm (Weinheim). 2010 Feb;343(2):73-80.
产品手册
关联产品
-
TGN020
TGN-020 is an inhibitor of Aquaporin 4 (AQP4 IC50: 3.1 μM) the most abundant water channel in the brain.
-
2-Hydroxy-3-methylan...
2-Hydroxy-3-methylanthraquinone enhances apoptosis of U937 cells,in part,through activation of p-p38MAPK and downregulation of p-ERK1/2; triggers caspase-3 activation mediated apoptotic induction.
-
TMB
TMB is a chromogenic substrate. It used in staining procedures in immunohistochemistry and a visualizing reagent used in ELISA.
